Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NoCUT-BC in early-stage breast cancer
NCT07217990Phase 2Not yet recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in breast cancer (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Disease-Free Rate at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07217990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217990.